Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,010.60 +43.37 (+0.87%) Dow
38,239.98 +253.58 (+0.67%) Nasdaq
15,451.31 +169.30 (+1.11%) Bitcoin USD
66,005.23 +35.73 (+0.05%) CMC Crypto 200
1,421.70 +6.94 (+0.49%)
Supernus Pharmaceuticals, Inc. (SUPN)
After hours:
| Previous close | 29.40 |
| Open | 29.56 |
| Bid | 29.65 x 200 |
| Ask | 29.74 x 100 |
| Day's range | 29.30 - 30.30 |
| 52-week range | 21.99 - 38.09 |
| Volume | |
| Avg. volume | 393,080 |
| Market cap | 1.626B |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | 1,485.50 |
| EPS (TTM) | 0.02 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.50 |
BenzingaSupernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
GlobeNewswireSupernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD
- GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob
